Previous Close | 2.1000 |
Open | 2.1000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 2.1000 - 2.1000 |
52 Week Range | 2.1000 - 11.2500 |
Volume | |
Avg. Volume | 2 |
Market Cap | 52.68M |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1080 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
LYON, France, May 17, 2022--POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today provided a corporate update and announced its cash position and revenue for the first quarter ended March 31, 2022.
LYON, France, May 17, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL065 and PXL770 for the treatment of patients with adrenomyeloneuropathy (AMN), the most common
LYON, France, May 13, 2022--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21st, 2022 at 9 am CEST at Collège Hôtel, 5 Place Saint-Paul, 69005 LYON.